Huang, Sicong
He, Xintong
Doyle, Tracy J.
Zaccardelli, Alessandra
Marshall, Allison A.
Friedlander, H. Maura
Blaustein, Rachel B.
Smith, Elisabeth A.
Cui, Jing
Iannaccone, Christine K.
Mahmoud, Taysir G.
Weinblatt, Michael E.
Dellaripa, Paul F.
Shadick, Nancy A.
Sparks, Jeffrey A. http://orcid.org/0000-0002-5556-4618
Funding for this research was provided by:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (K23 AR069688, L30 AR066953, P30 AR070253, P30 AR072577, R03 AR075886)
National Heart, Lung, and Blood Institute (K23 HL119558)
Rheumatology Research Foundation (K Supplement Award)
Brigham Research Institute (Microgrant)
Article History
Received: 28 April 2019
Revised: 11 July 2019
Accepted: 31 July 2019
First Online: 13 August 2019
Change Date: 4 February 2020
Change Type: Correction
Change Details: The publisher regrets that the two sections under the Results omitted inadvertently on the original published version of the above article.
Compliance with ethical standards
: The study protocol and informed consent document were reviewed and approved by the Partners HealthCare Institutional Review Board. All subjects provided written informed consent before participating in the BRASS registry.
: Tracy J. Doyle reports research funding from Bristol-Myers Squibb and involvement in a clinical trial funded by Genentech. Paul F. Dellaripa reports research funding from Bristol-Myers Squibb and involvement in a clinical trial funded by Genentech. Michael E. Weinblatt reports research grants from Amgen, Crescendo Bioscience, Sanofi/Regeneron, and Bristol-Myers Squibb; consultancy to Abbvie, Amgen, Bristol-Myers Squibb, Canfite, Corrona, Crescendo Bioscience, GlaxoSmithKline, Gilead, Lilly, Lycera, Merck, Novartis, Pfizer, Roche, Samsung, Set Point, and Scipher; and stock options in Lycera, Canfite, Scipher, Vorso, and Inmedix. Nancy A. Shadick reports research funding from Bristol-Myers Squibb, Crescendo Biosciences, Sanofi Regeneron, and Mallinckrodt; and consultancy to Bristol-Myers Squibb. Jeffrey A. Sparks reports research funding from Bristol-Myers Squibb and Amgen and consultancy to Optum.